Skip to Content
Merck

N6514

Neuraminidase from Vibrio cholerae

Type II, buffered aqueous solution, 8-24 units/mg protein (Lowry, using NAN-lactose)

Synonym(s):

Acyl-neuraminyl Hydrolase, Receptor-destroying enzyme, Sialidase

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

CAS Number:
9001-67-6
UNSPSC Code:
12352204
NACRES:
NA.54
EC Number:
232-624-6
MDL number:
MFCD00131711
EC Number:
3.2.1.18 (BRENDA, IUBMB)

Product Name

Neuraminidase from Vibrio cholerae, Type II, buffered aqueous solution, 8-24 units/mg protein (Lowry, using NAN-lactose)

biological source

Vibrio cholerae

type

Type II

form

buffered aqueous solution

specific activity

8-24 units/mg protein (Lowry, using NAN-lactose)

foreign activity

Protease and NAN-aldolase, present

storage temp.

2-8°C

Quality Level

200

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Calorimetry studies show that the two lectin-like domains flanking the central catalytic domain of Neuraminidase serve as the recognition and binding sites for sialic acid-containing substrates.
Neuraminidase enzymes are hydrolase enzymes that promote influenza virus release from infected cells and facilitate virus spread.

Other Notes

One unit will liberate 1.0 μmole of N-acetylneuraminic acid per min at pH 5.0 at 37 °C using NAN-lactose or bovine submaxillary mucin, unless otherwise specified. Prices based on units using NAN-lactose as substrate.

Physical form

Solution in 50 mM sodium acetate, pH 5.5, containing 0.15 M sodium chloride and 4 mM calcium chloride, 0.2 μm filtered..

Preparation Note

A further purification by affinity chromatography of our Type III.

Application

Neurminidase is used as a cell-surface probe for glycoconjugate distribution and in substrate specificity studies.
Neuraminidase from Vibrio cholera has been used in a study to describe a five-step purification method. It has also been used in a study to investigate modification of leukemia L1210 tumor cells.

Analysis Note

Preservative free.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H334

Hazard Classifications

Resp. Sens. 1

Storage Class

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000496094
0000496094
0000345920
0000345920
0000288201

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.
J G Bekesi et al.
Cancer research, 31(12), 2130-2132 (1971-12-01)
Hirokazu Kai et al.
Bioorganic & medicinal chemistry, 20(8), 2739-2746 (2012-03-14)
A selective and potent inhibitor of neuraminidases, a hydrolase that is responsible for processing sialylated glycoconjugates, is a promising drug candidate for various infective diseases. The current study demonstrates that the use of an aglycone-focused library of 2-difluoromethylphenyl α-sialosides is
Paul Clark et al.
Viruses, 12(10) (2020-10-24)
Polyomaviruses are small, non-enveloped DNA tumor viruses that cause serious disease in immunosuppressed people, including progressive multifocal leukoencephalopathy (PML) in patients infected with JC polyomavirus, but the molecular events mediating polyomavirus entry are poorly understood. Through genetic knockdown approaches, we
Ibrahim Moustafa et al.
The Journal of biological chemistry, 279(39), 40819-40826 (2004-07-01)
Vibrio cholerae neuraminidase (VCNA) plays a significant role in the pathogenesis of cholera by removing sialic acid from higher order gangliosides to unmask GM1, the receptor for cholera toxin. We previously showed that the structure of VCNA is composed of
Matthew D Lauver et al.
eLife, 9 (2020-09-18)
JCPyV polyomavirus, a member of the human virome, causes progressive multifocal leukoencephalopathy (PML), an oft-fatal demyelinating brain disease in individuals receiving immunomodulatory therapies. Mutations in the major viral capsid protein, VP1, are common in JCPyV from PML patients (JCPyV-PML) but
View All Related Papers

Articles

Sialic Acid

Understand sialic acid structure, function, signaling, and modifications. Easily find products for sialic acid research.

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service